Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

RemeGen Co., Ltd.*

榮昌生物製藥(煙台)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

DISCLOSEABLE TRANSACTION
PURCHASE OF WEALTH MANAGEMENT PRODUCT

PURCHASE OF WEALTH MANAGEMENT PRODUCT

At the 21st meeting held by the second session of the Board on March 27, 2025, a resolution regarding cash management using self-owned funds of the Company was considered and approved, pursuant to which the Company may purchase principal guaranteed bank wealth management products using part of idle self-owned funds of not more than RMB500.0 million.

The Board announced that, on August 12, 2025, the Company entered into the CMB Wealth Management Product Agreement with CMB Yantai Branch, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB350.0 million from CMB Yantai Branch using idle self-owned funds.

LISTING RULES IMPLICATIONS

As one of the applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules) in respect of the CMB Wealth Management Product Agreement exceeds 5% but all of the applicable percentage ratios are less than 25%, the purchase of wealth management product under the CMB Wealth Management Product Agreement constitutes discloseable transaction of the Company under Chapter 14 of the Listing Rules and is subject to the reporting and announcement requirements under the Listing Rules.

BACKGROUND

The Board announced that, on August 12, 2025, the Company entered into the CMB Wealth Management Product Agreement with CMB Yantai Branch, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB350.0 million from CMB Yantai Branch using idle self-owned funds.

CMB WEALTH MANAGEMENT PRODUCT AGREEMENT

The principal terms of the CMB Wealth Management Product Agreement are set out as follows:

Name of the wealth management product	:	Gold-linked Series Bullish Two-tier 15-day Structured Deposit of CMB* (招商銀行點金系列看漲兩層區間 15 天結構性存款)
Type of product	:	Principal-guaranteed with floating income
Linked target	:	Gold
Principal amount	:	RMB350.0 million
Validity period of product	:	15 days
Effective date of product	:	August 13, 2025
Expiry date of product	:	August 28, 2025
Expected annualized yield rate	:	1.0% or 1.5%
Right of early termination	:	Upon the establishment of the product, should there be circumstances including but not limited to "material adjustments to national financial policies that affect the normal operation of the product", CMB has the right, but not the obligation, to early terminate the product.
Investment scope	:	The principal of such product will be invested in bank deposits and derivative financial instruments. Derivative financial instruments include, but are not limited to, credit, equity, commodity, foreign exchange and interest rate options, etc.

The terms of the CMB Wealth Management Product Agreement were determined upon arm's length negotiations between the parties.

INFORMATION ON THE PARTIES

The Company is a commercial-ready biopharmaceutical company committed to the discovery, development and commercialization of innovative and differentiated biologics for the treatment of autoimmune, oncology and ophthalmic diseases with unmet medical needs in China and globally.

CMB is a bank incorporated in the PRC, the shares of which are listed on the Stock Exchange (stock code: 3968) and on the Shanghai Stock Exchange (stock code: 600036). The principal businesses of CMB are the provision of corporate and personal banking services, conducting treasury business, the provision of asset management and other financial services. CMB Yantai Branch is a branch of CMB.

To the best knowledge, information and belief of the Directors having made all reasonable enquiries, CMB Yantai Branch, CMB and their ultimate substantial beneficial owners as publicly disclosed by CMB are third parties independent from the Company and its connected persons.

REASONS FOR AND BENEFITS OF ENTERING INTO THE CMB WEALTH MANAGEMENT PRODUCT AGREEMENT

The reasonable and efficient use of idle self-owned funds will enhance the overall capital gain of the Company, which is consistent with the core objectives of the Company to ensure capital safety and liquidity. The impact of risk factors on the expected return of the CMB Wealth Management Product Agreement is low, but the Company could get a higher rate of return as compared with fixed-term deposit in commercial banks in the PRC.

The Directors consider that the terms of the CMB Wealth Management Product Agreement and the transaction contemplated thereunder are fair and reasonable, on normal commercial terms or better in the ordinary course of business of the Group, and are in the interests of the Company and its Shareholders as a whole.

LISTING RULES IMPLICATIONS

As one of the applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules) in respect of the CMB Wealth Management Product Agreement exceeds 5% but all of the applicable percentage ratios are less than 25%, the purchase of wealth management product under the CMB Wealth Management Product Agreement constitutes discloseable transaction of the Company under Chapter 14 of the Listing Rules and is subject to the reporting and announcement requirements under the Listing Rules.

DEFINITIONS

Unless the context otherwise requires, the following terms used herein have the following meanings:

"Board"	the board of Directors
"CMB"	China Merchants Bank Co., Ltd., a bank incorporated in the PRC
"CMB Wealth Management Product Agreement"	the wealth management product agreement entered into between the Company and CMB Yantai Branch dated August 12, 2025 in relation to the purchase of wealth management product in the amount of RMB350.0 million
"CMB Yantai Branch"	Yantai Branch of China Merchants Bank Co., Ltd.
"Company"	RemeGen Co., Ltd.* (榮昌生物製藥(煙台)股份有限公司), a company incorporated in the PRC with limited liability, the H shares and A shares of which are listed on the Main Board of the Stock Exchange (stock code: 9995) and the Science and Technology Innovation Board of the Shanghai Stock Exchange (stock code: 688331), respectively
"connected person"	has the meaning ascribed to it under the Listing Rules
"Director(s)"	the director(s) of the Company
"Hong Kong"	the Hong Kong Special Administrative Region of the People's Republic of China
"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
"PRC" or "China"	the People's Republic of China
"RMB"	Renminbi, the lawful currency of the PRC
"Shareholder(s)"	holder(s) of the shares of the Company
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"%"	percent

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive Director

Yantai, PRC
August 12, 2025

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Lin Jian and Mr. Wen Qingkai as the executive Directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive Directors, and Mr. Hao Xianjing, Mr. Chen Yunjin and Mr. Huang Guobin as the independent non-executive Directors.

* *For identification purpose only*